Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) in a research report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock. Separately, Cantor Fitzgerald reissued an overweight rating and set a $6.00 price target on shares of Lineage Cell […]

Related Keywords

United States ,America ,Donm Bailey , ,Vanguard Group Inc ,America Corp ,Geode Capital Management ,Securities Exchange Commission ,Blackrock Inc ,Lineage Cell Therapeutics Inc ,Cantor Fitzgerald ,Lineage Cell Therapeutics ,Free Report ,Cell Therapeutics ,Director Broadwood Partners ,Exchange Commission ,Director Don ,Street Corp ,Capital Management ,Get Free Report ,Lineage Cell Therapeutics Daily ,Nyseamerican Lctx ,Lctx ,Medical ,Reiterated Rating ,Hc Wainwright ,